

KERYX BIOPHARMACEUTICALS INC  
Form 8-K  
March 24, 2010

---

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 24, 2010

Keryx Biopharmaceuticals, Inc.  
(Exact Name of Registrant as Specified in Charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

000-30929  
(Commission File Number)

13-4087132  
(IRS Employer Identification No.)

750 Lexington Avenue  
New York, New York 10022  
(Address of Principal Executive Offices)

(212) 531-5965  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  - Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
- 
-

Item 2.02. Results of Operations and Financial Condition.

On March 24, 2010, Keryx Biopharmaceuticals, Inc. (“Keryx”) issued a press release announcing results of operations for the fourth quarter and year ended December 31, 2009. Keryx also announced that on Thursday, March 25, 2010 at 8:30am EDT, Keryx will host an investor conference call during which they will provide a brief financial overview of fourth quarter and year-end 2009 financial results and the business outlook for 2010. A copy of such press release is being filed as Exhibit 99.1 to this report and is incorporated herein by reference.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Keryx Biopharmaceuticals, Inc.  
(Registrant)

Date: March 24, 2010

By: /s/ James F. Oliviero  
James F. Oliviero  
Chief Financial Officer

---

INDEX TO EXHIBITS

Exhibit Number	Description
-------------------	-------------

99.1	Press Release dated March 24, 2010.
------	-------------------------------------

---